

From the Bench to the Office of Research: Two Tales

Presented By:

Byron Roberts, Ph.D.

UC Davis InnovationAccess

Zane Starkewolfe, Ph.D.

Associate Director, UC Davis Venture Catalyst

One UC DAVIS

Byron Roberts

Current Position: IP Officer

- Responsible for protecting IP generated at UC Davis and furthering tech transfer mission
 - Patent protection
 - Licensing
 - Confidentiality agreements
- Campus/staff/faculty support
 - Guidance to other units re: IP language in agreements (e.g. research agreements)
 - Education/guidance to faculty and staff:
 - How to avoid jeopardizing patent rights
 - When to file patent applications
- Interactions with non-UC parties
 - Investors, companies, other universities

Byron Roberts

Chronology

- 2001 – 2003: B.S. UC Davis – Genetics
 - 2001-2003: Undergrad research Rose Lab
- 2003 – 2005: Postgraduate Researcher
 - UC Davis Vet Med
 - Brain cancer research (basic science and translational)
- 2005 – 2011: Ph.D. Cornell University – Computational Biology & Medicine
 - Cardiac arrhythmias
 - Computational modeling cardiac tissue
- 2011 – 2014: Postdoctoral Fellow UC Davis – Pharmacology
 - Cardiac arrhythmias
 - Modeling effects of ischemia on antiarrhythmic drugs
- Summer 2013: Internship UC Davis InnovationAccess
- 2014 – Present: IP Officer UC Davis InnovationAccess

Byron Roberts

Preparation

- INTERNSHIP
- Patent Bar Exam preparation
- Audited courses UC Davis School of Law
- Online courses/webinars
 - National Council of Entrepreneurial Tech Transfer (ncet2.org)
 - Association of University Technology Managers (www.autm.net)
 - Licensing Executives Society (les.org)


Zane Starkewolfe

Current Position: Associate Director – Venture Catalyst

- Collaborate with University faculty and researchers to assist in forming and funding new startup ventures based on University technology
- Assist entrepreneurs with navigating internal processes relevant to University founders of startups and new ventures
- Organize and run SBIR/STTR workshops to support campus entrepreneurs.
- Facilitate interactions between campus researchers and entrepreneurial networks (mentors, service providers, investors etc.) including existing campus networks.
- Supports efforts to form early stage private and other capital for UC Davis researchers engaged in translational research




Zyvex was the first molecular nanotechnology company, with the vision of developing atomically precise manufacturing.




Cytoplex Biosciences

Company Description:
Cytoplex is the pioneer of NanoBio materials, sensors, nanomaterials and microdevices for the Life Science, Medical and Process Industries.





Mesolytics was developing a portable handheld medical diagnostic platform based on proven nanowire technology to serve the rapidly growing point-of-care testing market.



- Winner of the 2006 Big Bang! Business Plan Competition
- Fantastic Advisors
 - Dr. Judy Kjelstrom



Roadwise Technologies
Paving the way for clean energy



DynaFilm™



- Winner of People's Choice Award in the 2012 Big Bang! Business Plan Competition

BURRILL & COMPANY

Life Sciences: Venture Capital, Private Equity, Merchant Banking, Media


BURRILL SECURITIES
A division of Burrill & Company

PORTOLA CAPITAL
PARTNERS

Healthcare Advisory and Investment Firm

- Diversified global financial services firm focused on the life sciences industry
- Founded in 1994 and with more than \$1.5 billion in assets under management
- Businesses include venture capital, private equity, investment banking, and media
- Leverages the scientific and business networks of its team to establish unrivaled access and visibility in the life sciences industry
- Unique combination of resources and capabilities enables us to provide life sciences companies with capital, management expertise, insight, market intelligence, and analysis through investments, conferences, and publications
- Headquartered in San Francisco, with a global network of offices throughout the United States, Latin America, Europe and Asia
- Unique and effective platform for generating deal flow, assessing the scientific, commercial and investment viability of potential transactions, executing transactions and creating value for portfolio companies and clients
- G. Steven Burrill, Founder and CEO, has been involved in the growth and prosperity of the biotechnology industry for more than 45 years. Prior to founding Burrill & Company, he was with Ernst & Young for 28 years, directing and coordinating the firm's services to clients in the life sciences industries worldwide

About Burrill & Company



Exclusively Focused on Life Sciences

- Human Healthcare (Rx, Dx, devices, services, consumer digital health, informatics) from innovation to delivery
- Nutraceuticals/Wellness
- Agbio/Food
- Industrial/Bioenergy (biofuels)
- Enabling Technologies, including bionanotechnology

Venture Capital/Private Equity Fund Management

- The Burrill family of venture capital funds has over \$1.5 billion under management
- Exclusively invested in life science-based companies with breakthrough technologies and business models to meet the world's need for better healthcare, food and energy sources

Global Presence

- North America
- Rio De Janeiro, Brazil
- Tokyo
- Hong Kong/Taipei
- Moscow
- Zurich
- Kuala Lumpur
- Beijing

Investment Banking

- Burrill Securities assists life science companies with a comprehensive array of strategic and financial advisory services including mergers and acquisitions, capital raising, and licensing / partnering


Media

- Burrill Media provides insight, intelligence, and information on life sciences that are unmatched in the industry in print and digital media, and is the publisher/editor/writer of the Burrill Annual Report of the industry (25 years). Burrill organizes leading industry conferences and webinars globally and also is a leading co-sponsor of life science events




Burrill Securities Investment Banking Services

- Burrill Securities Investment Banking Team provides a broad and complementary range of services to address the needs of our clients at various stages in their growth, including capital formation, partnerships, mergers & acquisitions, global arbitrage and strategic advisory



- Closed Merger & Acquisition Transactions



Immutep announces proposed acquisition by Prima BioMed Ltd

Highlights

- Prima to acquire French biopharmaceutical company Immutep SA for up to US\$28 M
- Expands Prima BioMed presence in the rapidly growing immuno-oncology industry
- Diversifies Prima BioMed product pipeline and provides partnerships with global pharma companies
- Potential revenue streams through milestone payments and licensing agreements
- Up to US\$37.4 M funding from US institutional investor Bergen

Leadership Team

▼ **Frédéric Triebel, MD Ph.D.**

Chief Scientific Officer & Chief Medical Officer



Frédéric Triebel, MD Ph.D., Scientific and Medical Director of Immunology at Paris University centre in Paris, he discovered a research group at IGR who treated in Phase I/II immunotherapy trials. He

First trained as a clinical haematologist, Prof developed several research programs in immunop